The consequences of these conditions extend far beyond the endocrine system, with neurological and psychiatric effects emerging as critical yet under-recognized dimensions of the disease burden
Estimating the global and regional burden of lower respiratory infections attributable to leading pathogens and the protective effectiveness of immunization programs
2022 Exhibit 54: Distribution of Medicare Part B Add-on Payments, 2021 Exhibit 55: Reimbursement Method for Provider-Administered Drugs Paid Under the Commercial Medical Benefit, by Site of Care Exhibit 56: Reimbursement Method for Biosimilars of Provider-Administered Drugs Paid Under the Commercial Medical Benefit, 2021 Exhibit 57: Distribution of Hospitals Cost-to-Charge Ratio for Pharmaceuticals, 2023 Exhibit 58: Reimbursement Rate and Administration Cost for Provider-Administered Drugs Paid Under the Commercial Medical Benefit, by Site of Care, 2024 Exhibit 59: Markups for Provider Administered Specialty Drugs for Privately Insured Individuals, by Site of Care and 340B Status, 2020/2021 Exhibit 60: Commercial Medical Benefit Cost per Claim for Reference Biologics and Their Biosimilars, by Site of Care, 2019 to 2023 Exhibit 61: Hospital Reimbursement by Commercial Payers, Avastin and Its Biosimilars, by Payer and Product, 2025 Exhibit 62: Commercial Health Plans Site-of-Care Programs for Provider-Administered Specialty Drugs, by Plan Type, 2024 Exhibit 63: Cigna Healthcare, Number of Specialty Drugs Subject to Site-of-Care Medical Policy, 2018 to 2025 Exhibit 64: Patient Cost Sharing for Provider-Administered Drugs Exhibit 65: Medicare Part B Coinsurance Adjustments, 2023:Q2 to 2025:Q1 Exhibit 66: Annual Rebate per Medicare Advantage Beneficiary, by Extra Benefit Type, 2020 to 2025 Exhibit 67: Revenue Mix at Oncology Practices, by Category Exhibit 68: Specialty Physician Practice GPOs and Ownership, 2025 Exhibit 69: Share of Oncologists in Practices with Medically Integrated Dispensing, by Practice Setting, 2010 to 2024 Exhibit 70: Initial and Final Prescription Claim Status for Brand-Name Oral Oncology Therapies, by Site of Dispensing, 2023 Exhibit 71: U.S
Genomic imprinting (the activation of maternal or paternal genes) has not been well studied in AD, but the Tg promoter appears to be a candidate for epigenetic effects (silencing or activation of genes) in AITDs (72)
Extracellular loops 1 and 3 and their associated transmembrane regions of the calcitonin receptor-like receptor are needed for CGRP receptor function
